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Introduction {#s1}
============

Phthalates are man-made chemicals widely used in our daily life \[e.g., food wrappings, cosmetic products, children's toys, cleaning products, medical devices, pharmaceuticals, polyvinyl chloride (PVC) flooring, building materials\] because of their properties of transparency, durability, and flexibility ([@c40]; [@c10]; [@c3]). People can be exposed to phthalates through inhalation, dermal absorption (including air-to-skin transport), contact with contaminated surfaces, and use of personal care products and ingestion (including dietary ingestion and incidental ingestion) ([@c54]). Urinary concentrations of phthalate metabolite are the most reliable measures for exposure assessment ([@c54]). The ubiquitous presence of phthalates in the environment and the potential consequences of human exposure to phthalates have raised concerns, particularly in vulnerable populations such as pregnant women and infants. Prenatal and early life are critical in the development of the immune system; exposure to toxic pollutants during this period can result in an increased risk of adverse health outcomes later in life.

Animal as well as epidemiological studies in infants and children have found various health effects of specific phthalates, including abnormal reproductive outcomes ([@c40]; [@c1]; [@c43]; [@c6]; [@c34]), children's neurodevelopmental and behavioral problems ([@c60]; [@c20]; [@c15]), and asthma and allergies ([@c13]; [@c61]; [@c53]; [@c35]; [@c30]), although not consistently.

The prevalence of eczema in childhood, including its allergic-related phenotype, varies globally from 3% to 37% and is steadily increasing worldwide ([@c4]; [@c44]; [@c19]; [@c18]). The causes of eczema and of its increased prevalence are still unclear but are likely to be multifactorial in nature and depend on both genetic and environmental factors ([@c44]; [@c49]). During *in utero* life, the skin of the fetus may be exposed to various products absorbed by the mothers, including phthalates given that some phthalates have been detected in amniotic fluid ([@c32]). Later in life, children's dermal exposure can occur through the use of emollients, personal care products, and dermal contact with plastic products, soil, and dust, which can add to the total intake of certain phthalates through other routes such as inhalation and ingestion ([@c64]; [@c46]).

Eczema pathogenesis involves immunologic dysfunction and skin barrier defects ([@c49]). Phthalates might influence the epidermal barrier development processes, which can take several years to occur, and this influence could be stronger in allergic individuals due to the fragility of their mucosae. Although dermal absorption of phthalates and its impact on child health is established, contradictory results exist regarding eczema development after phthalate exposure *in utero* ([@c35]; [@c52]; [@c59]; [@c23]; [@c47]).

The objective of the present study was to evaluate the potential associations between maternal exposure to phthalates during the second trimester (between the 24th and 28th weeks) of pregnancy and occurrence of eczema phenotypes in male children in their first 5 y of life using data collected in the French EDEN mother--child prospective cohort study. The association was explored according to atopic status as defined by total immunoglobulin E (IgE) in a subsample of boys for which this assessment was available.

Methods {#s2}
=======

Study Population and Data Collection {#s2.1}
------------------------------------

The population in this study is a subgroup of the French EDEN (Etude des Déterminants pré et post natals du développement de la santé de l'Enfant) mother--child prospective birth cohort restricted to boys (<https://eden.vjf.inserm.fr>). The mothers' recruitment and follow-up procedures and methodological assumptions have been published in earlier studies ([@c26]; [@c48]). Briefly, women were given an appointment with a study midwife between the 24th and 28th gestational weeks, during which an interview on lifestyle factors was conducted and biological samples were collected. The information on the mothers and their newborns, including parity, mode of delivery, birth weight, gestational age, season of birth, behavioral, and environmental data were collected by the use of questionnaires, interviews, and obstetric and pediatric records. Boys were followed from birth to 5 y of age. The present study includes all male offspring for whom maternal urine samples had been analyzed for metabolites of phthalates as a part of previous studies ([@c17]; [@c41]; [@c14]), which explains why we had only boys in the study. Restricting to one sex could be an advantage in the context where sex-specific effects of exposures are expected ([@c24]; [@c63]); a study restricted to one sex likely has a higher statistical power than a study including both.

Urine Collection and Analysis {#s2.2}
-----------------------------

Women were invited for a clinical examination and to provide a first morning urine at home before the hospital study visit between the 24th and 28th gestational weeks (second trimester of the pregnancy). If forgotten, the urine sample was collected at the hospital. A polypropylene container \[FP40VPS; Centre Européen de Biotechnologie SA (CEB), Angers, France\] was used. The urine samples were aliquoted and then frozen at $- 80{^\circ}C$. The analyses of the samples were conducted at the National Center for Environment Health Laboratory at the Centers for Disease Control and Prevention (CDC) in Atlanta, Georgia (USA) for 11 metabolites of 8 phthalates: diethyl phthalate (DEP), di-*n*-butyl phthalate (DBP), di-isobutyl phthalate (diBP), di(2-ethylhexyl) phthalate (DEHP), benzylbutyl phthalate (BBzP), di-isononyl phthalate (diNP), di-*n*-octyl phthalate (DOP), and di-isodecyl phthalate (DiDP).

The targeted phthalate metabolites were monoethyl phthalate (MEP), mono-*n*-butyl phthalate (MBP), mono-isobutyl phthalate (MiBP), mono(2-ethyl-5-carboxypentyl) phthalate (MECPP), mono(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP), mono(2-ethyl-5-oxohexyl) phthalate (MEOHP), mono(2-ethylhexyl) phthalate (MEHP), monobenzyl phthalate (MBzP), monocarboxy-isooctyl phthalate (MCOP), mono(3-carboxypropyl) phthalate (MCPP), and monocarboxy-isononyl phthalate (MCNP).

Quantification of the phthalate metabolites concentrations was performed using on-line solid phase extraction--high-performance liquid chromatography--electrospray ionization isotope dilution--tandem mass spectrometry ([@c51]). Creatinine concentrations were also quantified following the same analytical procedure described previously ([@c41]). The concentrations of metabolites below the limit of detection (LOD) were replaced by instrumental reading values or by the compound-specific lowest instrumental reading value divided by the square root of 2 when the instrumental value was missing ([@c29]). The vast majority of the samples/metabolites ($> 97\%$) were above LOD. Two-step standardization was performed to reduce variability in the urinary concentrations of biomarkers due to sampling conditions, as described previously ([@c41]). There was no significant difference in the concentrations of phthalates in the urine samples collected at homes compared with those collected in the hospital.

Eczema Phenotypes {#s2.3}
-----------------

Eczema was assessed by administration of an enriched version of the International Study of Asthma and Allergies in Childhood (ISAAC) standardized and validated questionnaire ([@c31]; [@c62]) to the parents at the children's ages of 1, 2, 3, 4, and 5 y by appointment. At each year of follow-up, eczema was defined as eczema diagnosed by a doctor in the last 12 mo. Ever eczema was then defined as having ever reported a diagnosis of eczema at 1, 2, 3, 4, or 5 y of age. Additionally, two eczema phenotypes were distinguished: early-onset eczema if eczema was reported on any questionnaire in the first 2 y of life, and late-onset eczema if it was reported only between 24 and 60 mo of age.

IgE and Atopic Status {#s3}
=====================

Total serum IgE was assessed in 293 boys at 5 y of age by using the CAP assay according to the manufacturers' instructions (Pharmacia CAP System™, Pharmacia and Upjohn Diagnostics AB, Uppsala, Sweden). Boys were classified as atopic if they had IgE levels of $\geq 60\,\text{IU}/{mL}$ ([@c7]).

Other Variables {#s3.1}
---------------

Information on potential confounders related to the children's eczema included birth weight, gestational age (two-class variable: $< 37$ gestational week, $\geq 37$ gestational week), season of birth, parity, number of siblings (0, 1, 2, $\geq 3$), exclusive breast-feeding for $\geq 4\,\text{mo}$ (yes/no), maternal age at delivery ($< 25\; y$, 25--29 y, 30--34 y, $\geq 35\; y$), pre-pregnancy maternal body mass index (BMI, $< 18.5$, 18.5--24.9, 25.0--30.0, $> 30\,{{kg}/m}^{2}$), maternal and paternal history of allergies, maternal and paternal educational level ($< 2\; y$ after high school, $\text{high}\,\text{school} + 2\; y$, $\geq \text{high}\,\text{school}$ $+ 3\; y$), household income, city of residence (Nancy/Poitiers), mode of delivery (vaginal, cesarean section), smoking during pregnancy (yes/no), maternal alcohol use during pregnancy (yes/no), maternal and paternal physician-diagnosed cases of asthma, rhinitis, eczema, and food allergies (yes/no).

Statistical Analysis {#s3.2}
--------------------

Urinary concentrations of phthalate metabolites were log-transformed because of nonnormality of the distribution. For the purpose of present analysis, MECPP, MEHHP, MEOHP, and MEHP were grouped as the sum of $\Sigma\text{DEHP}$ (DEHP being their parent compound). We calculated the molar sum of these DEHP metabolites (nanomoles per milliliter) by dividing each metabolite concentration by its molecular weight and then summing the individual concentrations.

The prevalence and the incidence of eczema were computed. We applied multiple logistic regression analysis to examine the association between each phthalate metabolite and $\Sigma\text{DEHP}$ and eczema outcomes adjusted for potential confounders. The potential confounders were determined *a priori* from literature review. Then we used Directed Acyclic Graph (<http://www.dagitty.net/dags.html>) to show the hypothesis relations between biomarkers concentration, confounders, and eczema outcomes (see Figure S1). The confounders included in our final model were parental asthma/rhinitis/eczema, maternal smoking, maternal age, maternal BMI, maternal education level, gestational age, and number of siblings. Models were additionally adjusted for recruitment center.

We also applied the Cox proportional hazard discrete time survival model to estimate the association between *in utero* exposure to phthalates and eczema occurrence in the first 5 y of life after adjustment for the confounding factors. Results were further stratified in order to see whether phthalate biomarkers were associated with atopic (presence of allergic sensitization according to IgE) or nonatopic (absence of allergic sensitization to IgE) eczema. We also took IgE as an additional variable to see its association with phthalate biomarkers by applying multiple logistic regression analysis. Because our statistical analysis involved multiple comparisons so that it became increasingly likely that at least one comparison would have been statistically different due to random sampling error alone, the multiple testing hypothesis was considered using the Bonferroni test. All the statistical analysis was conducted using Stata statistical software (version 14; Stata Corporation), where $p < 0.05$ was considered statistically significant.

Ethics Approval {#s3.3}
---------------

The study was approved by the relevant ethical committees (Comité Consultatif pour la Protection des Personnes dans la Recherche Biomédicale, Le Kremlin Bicêtre University Hospital, and Commission Nationale de l'Informatique et des Libertés), and all participating women gave informed written consent for their own participation, and both parents for a newborn child after delivery.

Results {#s4}
=======

Characteristics of the Population {#s4.1}
---------------------------------

There were 998 male offspring in the cohort, among whom 604 had phthalates assessment. The participants included in this study analysis did not differ in major demographic characteristics from the other EDEN boys ([Table 1](#t1){ref-type="table"}) except for maternal age. However, results did not change when adjusting for maternal age in the final model. Average maternal age was 29.9 y, 26.3% women were overweight or obese ($\text{BMI} > 25{\,{kg}/m}^{2}$), and 85.8% did not smoke during pregnancy. There were 24 (4.0%) boys born before the 37th week of gestation, and 15 (3.0%) had a birth weight $< 2,500\; g$. Ninety-five (15.7%) mothers delivered through cesarean section. Urine was reported as being collected before 0800 hours 51.3% of the time, and between 0800 and 1200 hours 24.7% of the time. We also observed that during pregnancy 14.4% of the mothers had eczema, 10.9% had asthma, and 16.7% had rhinitis.

###### 

Characteristics of the study population and comparison with the entire EDEN cohort of boys.

Table 1 lists characteristics in the first column; the corresponding number and percentage for All male EDEN cohort (n equals 998) and present study (n equals 604), and the corresponding p values are listed in the other columns.

  Characteristics                               All male EDEN cohort ($n = 998$)   Present study ($n = 604$)   *p*-Value          
  --------------------------------------------- ---------------------------------- --------------------------- ----------- ------ --------
  Maternal age (y)                                                                                                                
   $< 25$                                       200                                20.0                        79          13.0    
   25--29                                       378                                37.9                        218         36.1    
   30--34                                       285                                28.6                        205         34.0    
   $\geq 35$                                    135                                13.5                        102         16.9   0.0006
  Parity                                                                                                                          
   0                                            436                                43.7                        269         44.5    
   1                                            374                                37.5                        222         36.8    
   $\geq 2$                                     187                                18.7                        112         18.6    
   Missing                                      1                                  0.1                         1           0.1    0.9
  BMI (${{kg}/m}^{2}$)                                                                                                            
   $< 18.5$                                     92                                 9.2                         57          9.4     
   18.5--24.9                                   634                                63.6                        379         62.9    
   25--30                                       171                                17.1                        110         18.3    
   $> 30$                                       80                                 8.0                         49          8.1     
   Missing                                      21                                 2.1                         9           1.5    0.8
  Maternal education                                                                                                              
   $< 2\; y$ after high school                  459                                46.0                        263         43.5    
   $\text{High}\,\text{school} + 2\; y$         219                                21.9                        132         21.9    
   $\geq \text{High}\,\text{school}$$+ 3\; y$   297                                29.8                        199         32.9    
   Missing                                      23                                 2.3                         10          1.7    0.4
  Active smoking (cigarettes/day)                                                                                                 
   0                                            827                                82.9                        518         86.0    
   1--5                                         82                                 8.2                         45          7.5     
   $> 5$                                        86                                 8.6                         37          6.2     
   Missing                                      3                                  0.3                         2           0.3    0.2
  Passive smoking                                                                                                                 
   Yes                                          278                                27.9                        192         31.8    
   No                                           711                                71.2                        405         67.1    
   Missing                                      9                                  0.9                         7           1.1    0.2
  Alcohol during pregnancy                                                                                                        
   Yes                                          278                                27.9                        151         25.0    
   No                                           714                                71.5                        450         74.5    
   Missing                                      6                                  0.6                         3           0.5    0.4
  Center                                                                                                                          
   Poitiers                                     533                                53.4                        347         57.4    
   Nancy                                        465                                46.6                        257         42.6   0.1
  Gestational age                                                                                                                 
   $< 37$ gestational week                      63                                 6.3                         24          4.0     
   $\geq 37$ gestational week                   935                                93.7                        580         96.0   0.04
  Birth weight                                                                                                                    
   $< 2,500\; g$                                47                                 4.7                         15          2.5     
   $\geq 2,500\; g$                             951                                95.3                        589         97.5   0.02
  Year of birth                                                                                                                   
   2003--2004                                   560                                56.1                        330         54.6    
   2005--2006                                   438                                43.9                        274         45.4   0.5
  Breast-feeding                                                                                                                  
   Yes                                          720                                72.2                        432         71.5    
   No                                           270                                27.0                        172         28.5    
   Missing                                      8                                  0.8                         0           0      0.07
  Employment                                                                                                                      
   Yes                                          727                                72.9                        458         75.9    
   No                                           262                                26.2                        142         23.5    
   Missing                                      9                                  0.90                        4           0.6    0.3
  Cesarean section                                                                                                                
   Yes                                          175                                17.5                        95          15.7    
   No                                           822                                82.4                        509         84.3    
   Missing                                      1                                  0.1                         0           0      0.4
  Marital status                                                                                                                  
   Married                                      534                                53.6                        329         54.5    
   Unmarried/single                             435                                43.5                        257         42.6    
   Divorced                                     19                                 1.9                         12          1.9     
   Separated                                    2                                  0.2                         2           0.3     
   Widowed                                      2                                  0.2                         1           0.2     
   Missing                                      6                                  0.6                         3           0.5    0.9
  Season of urine sample collection                                                                                               
   Winter                                       262                                26.2                        189         31.3    
   Spring                                       301                                30.2                        146         24.2    
   Summer                                       249                                24.9                        129         21.3    
   Fall                                         186                                18.7                        140         23.2   0.002
  Time of sampling                                                                                                                
   2400--0759 hours                             500                                50.1                        310         51.3    
   0800--1159 hours                             272                                27.3                        149         24.7    
   1200--1900 hours                             7                                  0.7                         5           0.8     
   Missing                                      219                                21.9                        140         23.2   0.7
  Maternal history of asthma                                                                                                      
   Yes                                          110                                11.0                        66          10.9    
   No                                           884                                88.6                        536         88.7    
   Missing                                      4                                  0.4                         2           0.3    0.9
  Maternal history of eczema                                                                                                      
   Yes                                          142                                14.2                        87          14.4    
   No                                           852                                85.4                        515         85.3    
   Missing                                      4                                  0.4                         2           0.3    0.9
  Maternal history of rhinitis                                                                                                    
   Yes                                          167                                16.7                        101         16.7    
   No                                           827                                82.9                        501         83.0    
   Missing                                      4                                  0.4                         2           0.3    0.9
  Paternal history of asthma                                                                                                      
   Yes                                          99                                 9.9                         58          9.6     
   No                                           895                                89.7                        544         90.1    
   Missing                                      4                                  0.4                         2           0.3    0.9
  Paternal history of eczema                                                                                                      
   Yes                                          48                                 4.8                         24          4.0     
   No                                           946                                94.8                        578         95.7    
   Missing                                      4                                  0.4                         2           0.3    0.7
  Paternal history of rhinitis                                                                                                    
   Yes                                          100                                10.0                        60          9.9     
   No                                           894                                89.6                        542         89.8    
   Missing                                      4                                  0.4                         2           0.3    0.3

Note: BMI; body mass index.

Eczema Prevalence and Incidence {#s4.2}
-------------------------------

The prevalence of ever eczema was 9.7%, 15.7%, 21.0%, 26.6%, and 30.4% at 1, 2, 3, 4, and 5 y of age, respectively. The incidence decreased from 9.7% at 1 y of age to 5.2% at 5 y of age ([Figure 1](#f1){ref-type="fig"}). The prevalence of early-onset and late-onset eczema were 15.7% and 14.7%, respectively.

![The incidence of eczema with age of the boys. The *y*-axis shows the percentage, and the numbers above each bar indicate the number of boys diagnosed at each year of age.](EHP1829_f1){#f1}

Prenatal Exposure to Phthalates {#s4.3}
-------------------------------

Phthalate metabolites were detected in the urine of more than 97% of the mothers. MEP had the highest geometric mean ($110.7\;\mu g/L$), whereas MCNP had the lowest ($1.5\;\mu g/L$). The LOD ranged from 0.2 to $0.6\;\mu g/L$. A summary of detection frequency as well as geometric means and select percentiles of urinary concentrations of phthalate metabolites are outlined in [Table 2](#t2){ref-type="table"}.

###### 

Distribution of phthalate metabolites concentration ($\mu g/L$) in maternal prenatal urine ($n = 604$).

Table 2 lists parent compound and their corresponding abbreviations are listed in the first and second columns, respectively. The phthalate metabolites and their corresponding abbreviations are listed in the third and fourth columns, respectively. Their corresponding LOD in micrograms per liter, percentage greater than LOD, geometric mean, minimum values, 5th, 25th, 50th, 75th, and 95th percentiles, and maximum values are listed in the other columns.

  Parent compound              Abbrev   Phthalate metabolites ($\mu g/L$)         Abbrev   LOD ($\mu g/L$)   $\% > \text{LOD}$   GM      Minimum   Percentile   Maximum                     
  ---------------------------- -------- ----------------------------------------- -------- ----------------- ------------------- ------- --------- ------------ --------- ----- ----- ----- --------
  Diethyl phthalate            DEP      Monoethyl phthalate                       MEP      0.6               100                 110.7   7.9       21           51        96    195   714   4093.4
  Di-*n*-butyl phthalate       DBP      Mono-*n*-butyl phthalate                  MBP      0.2               100                 51.6    2.8       12           28        43    73    438   2418.8
  Di-isobutyl phthalate        DiBP     Mono-isobutyl phthalate                   MiBP     0.2               100                 42.7    1.5       12           25        39    69    166   689.9
  Di(2-ethylhexyl) phthalate   DEHP     Mono(2-ethyl-5-carboxypentyl) phthalate   MECPP    0.2               100                 40.5    2.6       12           25        38    62    160   2640.5
  Di(2-ethylhexyl) phthalate   DEHP     Mono(2-ethyl-5-hydroxyhexyl) phthalate    MEHHP    0.2               100                 26.9    1.7       6.8          16        27    44    103   2103.8
  Di(2-ethylhexyl) phthalate   DEHP     Mono(2-ethyl-5-oxohexyl) phthalate        MEOHP    0.2               99.7                22.1    0.6       5.6          14        23    36    84    1441.4
  Di(2-ethylhexyl) phthalate   DEHP     Mono(2-ethylhexyl) phthalate              MEHP     0.5               98                  7.2     0.1       1.6          4.4       7.7   15    35    292.3
  Benzylbutyl phthalate        BBzP     Monobenzyl phthalate                      MBzP     0.3               100                 19.7    1.6       4.5          11        18    33    104   970.4
  Di-isononyl phthalate        DiNP     Monocarboxy-isooctyl phthalate            MCOP     0.2               99                  4.1     0.1       1.2          2.4       3.9   6.5   19    375.3
  Di-*n*-octyl phthalate       DOP      Mono(3-carboxypropyl) phthalate           MCPP     0.2               100                 2.1     0.1       0.7          1.3       1.9   3.4   9.1   78.7
  Di-isodecyl phthalate        DiDP     Monocarboxy-isononyl phthalate            MCNP     0.2               97.5                1.5     0.1       0.5          0.8       1.2   2.2   9.5   686.8

Note: Abbrev, abbreviation; GM, geometric mean; LOD, limit of detection.

Spearman correlation coefficients between ln-transformed phthalate metabolites urinary concentrations are shown in Table S1. The majority of biomarkers were positively correlated except for the correlation between MEP and MiBP, MECPP, MEHHP, MCOP, MCPP, or MCNP. All the other biomarkers were significantly correlated with each other (with correlation coefficients ranging from $r = 0.08$, $p < 0.05$ to $r = 0.97$, $p < 0.05$). As expected, DEHP metabolites were highly correlated with each other ($r \geq 0.77$, $p < 0.05$).

Associations between Phthalates Metabolites and Eczema Phenotypes {#s4.4}
-----------------------------------------------------------------

[Table 3](#t3){ref-type="table"} presents the relationship of prenatal phthalate exposure (based on phthalate metabolite urinary concentrations) to the occurrence of ever eczema outcomes in boys between 1 and 5 y of age. Based on a multiple logistic regression model that was adjusted for confounding factors, we observed an increased risk of eczema at 1 y of age in association with increased MEP concentrations \[odds ratio $\left( \text{OR} \right) = 1.69$; 95% confidence interval (CI): 1.05, 2.73; $p < 0.05$\] and at 1, 3, 4, and 5 y of age for MiBP.

###### 

Associations {adjusted odds ratio and 95% confidence interval \[OR (95% CI)\]} between maternal urinary concentrations of phthalate metabolites and occurrence of eczema phenotypes in boys ($n = 604$).

Table 3 lists years in the first column. The corresponding O R and 95 percent confidence intervals for MEP, MBP, MiBP, MECPP, MEHHP, and MEOHP are listed in the other columns.

  Year, eczema         MEP                                                   MBP                 MiBP                                                  MECPP                                                 MEHHP                                                MEOHP                                                MEHP                                                  MBzP                                                 MCOP                                                  MCPP                MCNP                                                  $\Sigma\text{DEHP}$
  -------------------- ----------------------------------------------------- ------------------- ----------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ---------------------------------------------------- ----------------------------------------------------- ------------------- ----------------------------------------------------- -----------------------------------------------------
  1                    1.69 (1.05, 2.73)[^\*^](#t3n1){ref-type="table-fn"}   1.17 (0.74, 1.84)   1.78 (0.95, 3.33)[^†^](#t3n2){ref-type="table-fn"}    1.04 (0.55, 1.98)                                     1.06 (0.61, 1.85)                                    1.07 (0.60, 1.92)                                    1.06 (0.61, 1.83)                                     1.10 (0.60, 2.00)                                    1.25 (0.70, 2.20)                                     1.15 (0.66, 2.00)   0.88 (0.59, 1.32)                                     1.01 (0.87, 1.18)
  2                    1.08 (0.74, 1.57)                                     1.12 (0.76, 1.63)   1.15 (0.64, 2.09)                                     0.94 (0.58, 1.52)                                     0.94 (0.60, 1.46)                                    0.97 (0.61, 1.54)                                    0.88 (0.57, 1.36)                                     1.14 (0.70, 1.87)                                    0.85 (0.52, 1.37)                                     1.18 (0.75, 1.87)   0.84 (0.55, 1.29)                                     0.98 (0.87, 1.10)
  3                    1.46 (0.89, 2.40)                                     1.12 (0.74, 1.69)   1.81 (0.94, 3.49)[^†^](#t3n2){ref-type="table-fn"}    0.72 (0.38, 1.34)                                     0.88 (0.50, 1.54)                                    0.90 (0.50, 1.60)                                    0.94 (0.61, 1.47)                                     1.14 (0.70, 1.86)                                    1.28 (0.79, 2.09)                                     1.09 (0.64, 1.85)   1.61 (1.00, 2.59)[^\*^](#t3n1){ref-type="table-fn"}   0.96 (0.84, 1.11)
  4                    1.03 (0.79, 1.33)                                     1.15 (0.87, 1.85)   1.68 (1.16, 2.45)[^\*^](#t3n1){ref-type="table-fn"}   1.32 (0.96, 1.83)[^†^](#t3n2){ref-type="table-fn"}    1.29 (0.95, 1.74)[^†^](#t3n2){ref-type="table-fn"}   1.30 (0.95, 1.77)[^†^](#t3n2){ref-type="table-fn"}   1.21 (0.91, 1.61)                                     1.24 (0.91, 1.69)                                    1.37 (0.99, 1.89)[^†^](#t3n2){ref-type="table-fn"}    1.11 (0.79, 1.56)   1.22 (0.95, 1.57)                                     1.07 (0.99, 1.15)[^†^](#t3n2){ref-type="table-fn"}
  5                    1.10 (0.86, 1.42)                                     1.10 (0.83, 1.47)   1.63 (1.12, 2.36)[^\*^](#t3n1){ref-type="table-fn"}   1.46 (1.04, 2.06)[^\*^](#t3n1){ref-type="table-fn"}   1.32 (0.96, 1.81)[^†^](#t3n2){ref-type="table-fn"}   1.33 (0.96, 1.85)[^†^](#t3n2){ref-type="table-fn"}   1.38 (1.03, 1.85)[^\*^](#t3n1){ref-type="table-fn"}   1.30 (0.96, 1.76)[^†^](#t3n2){ref-type="table-fn"}   1.60 (1.16, 2.23)[^\*^](#t3n1){ref-type="table-fn"}   1.19 (0.84, 1.69)   1.37 (1.04, 1.80)[^\*^](#t3n1){ref-type="table-fn"}   1.08 (1.00, 1.18)[^\*^](#t3n1){ref-type="table-fn"}
  Early-onset eczema   1.06 (0.89, 1.25)                                     1.10 (0.92, 1.32)   1.27 (1.00, 1.72)[^\*^](#t3n1){ref-type="table-fn"}   1.03 (0.77, 1.36)                                     1.02 (0.79, 1.32)                                    1.04 (0.80, 1.36)                                    1.06 (0.85, 1.32)                                     1.13 (0.88, 1.47)                                    1.29 (1.04, 1.60)[^\*^](#t3n1){ref-type="table-fn"}   1.18 (0.93, 1.49)   1.08 (0.90, 1.30)                                     0.98 (0.92, 1.04)
  Late-onset eczema    1.13 (0.90, 1.42)                                     1.17 (0.96, 1.42)   1.55 (1.10, 2.18)[^\*^](#t3n1){ref-type="table-fn"}   1.34 (1.00, 1.81)[^\*^](#t3n1){ref-type="table-fn"}   1.26 (0.96, 1.67)[^†^](#t3n2){ref-type="table-fn"}   1.28 (0.96, 1.70)[^†^](#t3n2){ref-type="table-fn"}   1.18 (0.92, 1.52)                                     1.19 (0.90, 1.57)                                    1.63 (1.20, 2.21)[^\*^](#t3n1){ref-type="table-fn"}   1.14 (0.83, 1.57)   1.29 (1.02, 1.64)[^\*^](#t3n1){ref-type="table-fn"}   1.06 (0.99, 1.13)[^†^](#t3n2){ref-type="table-fn"}

Note: Models were adjusted for parental asthma/rhinitis/eczema, maternal smoking, maternal age, maternal BMI, maternal education level, gestational age, number of siblings, and recruitment center. Note: BMI, body mass index; CI, confidence interval; DEHP, di(2-ethylhexyl) phthalate; MBP, mono-*n*-butyl phthalate; MBzP, Monobenzyl phthalate; MCNP, monocarboxy-isononyl phthalate; MCOP, monocarboxy-isooctyl phthalate; MCPP, mono (3-carboxypropyl) phthalate; MECPP, mono (2-ethyl-5-carboxypentyl) phthalate; MEHHP, mono (2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono (2-ethylhexyl) phthalate; MEOHP, mono (2-ethyl-5-oxohexyl) phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate; OR, odds ratio.

$p < 0.05$,

$p < 0.10$.

MBP and MCPP did not show significant associations at any age. MEHHP and MEOHP showed borderline significance at 4 and 5 y of age, respectively; whereas MECPP was of borderline significance at 4 y of age and significant at 5 y of age. MEHP was only significant at 5 y of age \[$\text{OR} = 1.38$ (95% CI: 1.03, 1.85), $p < 0.05$\]. $\Sigma\text{DEHP}$ was also of borderline significance at 4 y of age and significant at 5 y of age. Interestingly, MBzP was only found to be marginally significant at 5 y \[$\text{OR} = 1.30$ (95% CI: 0.96, 1.76), $p < 0.10$\]. We also observed that MCOP was marginally significant at 4 y of age and significant at 5 y of age, whereas MCNP showed significant results at 3 and 5 y of age.

In both phenotypes of eczema, MiBP and MCOP were positively associated with early-onset eczema \[$\text{OR} = 1.27$ (95% CI: 1.00, 1.72), $p < 0.05$ and $\text{OR} = 1.29$ (95% CI: 1.04, 1.60), $p < 0.05$, respectively\] as well as late-onset eczema \[$\text{OR} = 1.55$ (95% CI: 1.10, 2.18), $p < 0.05$ and $\text{OR} = 1.63$ (95% CI: 1.20, 2.21), $p < 0.05$, respectively\] after adjusting for potential confounders ([Table 3](#t3){ref-type="table"}). Other phthalate metabolites were not significantly associated with early-onset eczema. However in the case of late-onset eczema, MECPP and MCNP were positively associated \[$\text{OR} = 1.34$ (95% CI: 1.00, 1.81), $p < 0.05$ and $\text{OR} = 1.29$ (95% CI: 1.02, 1.64), $p < 0.05$, respectively\], whereas the association with MEHHP, MEOHP, and $\Sigma\text{DEHP}$ were of borderline significance ($p < 0.10$).

We also applied survival analysis to compute the hazard ratio (HR) of the occurrence of eczema in the first 5 y of life with respect to exposure to phthalates ([Table 4](#t4){ref-type="table"}). Both MiBP \[adjusted $\text{HR} = 1.16$ (95% CI: 1.01, 1.34), $p = 0.03$\] and MCOP \[$\text{HR} = 1.09$ (95% CI: 0.95, 1.25), $p = 0.05$\] were related to ever eczema after adjustment for potential confounders. No other phthalate was associated with the occurrence of eczema in this analysis.

###### 

Association (hazard ratio and 95% confidence interval) between maternal urinary concentrations of phthalate metabolites and occurrence of ever eczema in boys ($n = 184/604$).

Table 4 lists phthalate metabolites in the first column; the corresponding H R, 95 percent confidence interval, and p values for unadjusted and adjusted are listed in the other columns.

  Phthalate metabolite   Unadjusted   Adjusted[^*a*^](#t4n1){ref-type="table-fn"}                                                                 
  ---------------------- ------------ ---------------------------------------------- ------ ------ ---------------------------------------------- ------
  MEP                    1.04         0.93, 1.15                                     0.47   1.04   0.94, 1.16                                     0.42
  MBP                    1.00         0.89, 1.12                                     0.96   1.03   0.92, 1.15                                     0.60
  MiBP                   1.16         1.01, 1.33[^\*^](#t4n3){ref-type="table-fn"}   0.03   1.16   1.01, 1.34[^\*^](#t4n3){ref-type="table-fn"}   0.03
  MECPP                  0.97         0.84, 1.12                                     0.73   0.98   0.84, 1.13                                     0.77
  MEHHP                  0.99         0.86, 1.13                                     0.90   0.99   0.88, 1.14                                     0.93
  MEOHP                  1.01         0.88, 1.15                                     0.91   1.01   0.88, 1.16                                     0.86
  MEHP                   0.96         0.86, 1.07                                     0.50   0.96   0.85, 1.08                                     0.47
  MBzP                   0.99         0.88, 1.12                                     0.99   1.02   0.90, 1.15                                     0.69
  MCOP                   1.04         0.91, 1.19                                     0.48   1.09   0.95, 1.25[^†^](#t4n4){ref-type="table-fn"}    0.05
  MCPP                   1.02         0.88, 1.17                                     0.81   1.05   0.91, 1.22                                     0.50
  MCNP                   1.02         0.90, 1.14                                     0.74   1.03   0.92, 1.17                                     0.56
  $\Sigma\text{DEHP}$    0.99         0.96, 1.03                                     0.77   0.98   0.94, 1.03                                     0.57

Note: CI, confidence interval; DEHP, di(2-ethylhexyl) phthalate; HR, hazard ratio; MBP, mono-*n*-butyl phthalate; MBzP, monobenzyl phthalate; MCNP, monocarboxy-isononyl phthalate; MCOP, monocarboxy-isooctyl phthalate; MCPP, mono(3-carboxypropyl) phthalate; MECPP, mono(2-ethyl-5-carboxypentyl) phthalate; MEHHP, mono(2-ethyl-5-hydroxyhexyl) phthalate; MEHP, mono(2-ethylhexyl) phthalate; MEOHP, mono(2-ethyl-5-oxohexyl) phthalate; MEP, monoethyl phthalate; MiBP, mono-isobutyl phthalate.

$p < 0.05$,

$p < 0.10$.

HR adjusted for parental asthma/rhinitis/eczema, maternal smoking, maternal age, maternal BMI, maternal education level, gestational age, number of siblings, and recruitment center.

HR according to the proportional Cox's model.

Associations between Phthalate Metabolites and Ever Eczema According to Atopic Status {#s4.5}
-------------------------------------------------------------------------------------

We found significant associations between total IgE and phthalate metabolites, including $\Sigma\text{DEHP}$ ($p = 0.01$) and its metabolites MECPP ($p = 0.03$), MEHHP ($p = 0.005$), MEOHP ($p = 0.008$), and MEHP ($p = 0.04$). We further stratified eczema outcome by atopic status. Of the 293 boys tested for IgE, we observed that 60 (20.48%) were sensitized and 233 (79.52%) were not. Table S2 shows the associations between maternal urinary concentrations of phthalate metabolite and eczema outcomes in boys according to their atopic status. Among IgE-sensitized boys, MBP and MiBP were significantly associated with ever eczema \[$\text{HR} = 1.67$ (95% CI: 1.10, 2.54), $p = 0.01$ and $\text{HR} = 1.87$ (95% CI: 1.01, 3.48), $p = 0.04$, respectively\]. $\Sigma\text{DEHP}$ and MECPP, MEHHP, MEOHP, and MEHP individually were also positively associated with ever eczema in sensitized boys. MBzP was partially associated \[$\text{HR} = 1.47$ (95% CI: 0.98, 2.20), $p = 0.06$\]. However, the association for MEP, MCOP, MCPP, and MCNP was not significant. We did not find any association between prenatal phthalate exposure and eczema in boys without IgE sensitization. Using the multiple hypothesis testing did not modify the results except for MBP, MiBP, and MBzP, for which only a trend was observed.

Discussion {#s5}
==========

Major Findings {#s5.1}
--------------

In this study, we report an association between maternal prenatal urinary concentration of metabolites of DiBP and DiNP and eczema development in offspring preschool boys followed-up between birth and 5 y of age. Metabolites of DiBP and DiNP were significantly associated with both phenotypes of eczema (early and late onset) ([Table 4](#t4){ref-type="table"}). DiBP is used in nitrocellulose plastic, nail polish, lacquer manufacturing and used with methyl methacrylate applications, whereas DiNP is used in a diverse range of industrial products (such as electrical wire and cables, flexible PVC sheeting, coated fabrics, automotive parts), building and construction, and several categories of toys (plastic books, balls, dolls, and cartoon characters) ([@c33]).

MECPP, a DEHP metabolite, and MCNP, a DiDP metabolite, were positively associated with late-onset eczema, whereas MEHHP and MEOHP, two metabolites of DEHP, were marginally associated. Our study also suggests a significant association between prenatal exposure to various phthalates and allergic eczema in boys at 5 y of age based on IgE levels. The metabolites of DBP, DiBP, and DEHP were significantly associated with ever eczema in IgE-sensitized boys, and borderline significance was associated with MBzP, the major BBzP metabolite \[$\text{HR} = 1.47$ (95% CI: 0.98, 2.20), $p = 0.06$\].

Comparison of Findings with Other Published Work {#s5.2}
------------------------------------------------

Several studies have reported a potential relationship between phthalates exposure and asthma ([@c13]; [@c30]; [@c52]; [@c2]) and eczema ([@c13]; [@c53]; [@c35]; [@c30]; [@c52]; [@c2]) related symptoms in children. However, most of these studies used a case--control ([@c11], [@c13], [@c10], [@c12]) or cross-sectional ([@c30]; [@c2]; [@c28]) design or relied on phthalate levels in dust as a marker of phthalate exposure ([@c10]; [@c2]; [@c38]; [@c37]). This limits the conclusions that can be drawn because dust is not the only source of exposure to these chemicals.

In a birth cohort study in New York City where maternal urine was collected during the third trimester of pregnancy, MBzP, the major BBzP metabolite, was associated with the development of eczema by 5 y of age in 407 children ([@c35]). In Sweden, an association between BBzP levels in dust and atopic dermatitis was observed in cross-sectional data ([@c13]). In a cross-sectional study among 101 Taiwanese children between 3 and 9 y of age, BBzP levels in house dust were associated with eczema and asthma ([@c30]). However, in the present study we observed only partial association between the main metabolite of BBzP and eczema at 5 y of age, even in boys with allergic eczema. In our study the metabolites of DiBP and DiNP were significantly associated with early-onset and late-onset eczema as well as ever eczema in boys. In contrast, in a birth cohort with 1,024 mother--child pairs from Greenland and Ukraine, oxidative metabolites of DiNP in maternal serum were negatively associated with current eczema as well as with ever eczema in boys and girls from Greenland ([@c52]). One limitation of that study is that it was conducted in children between 5 and 9 y of age, because approximately 40--70% of childhood eczema cases resolve by the time the children reach 6--7 y of age ([@c49]).

Although phthalates are not highly sensitizing, they may promote the development of allergy or eczema ([@c58]). Studies on mouse models have shown that phthalates, including DEHP and DiNP at low doses, can aggravate atopic dermatitis/eczema-like skin lesions by direct or indirect activation of the immune cells, which can be responsible, at least in part, for the increase in the prevalence of atopic dermatitis/eczema ([@c36]; [@c50]; [@c65]). To date, a large amount of work has been done on DEHP and allergy; DEHP is banned in many industrialized countries in PVC toys that may be placed in the mouth by children $< 3\; y$ of age ([@c50]). DiNP is a substitute for DEHP, and this might be a reason for its increasing levels with time and the adverse effects associated with DiNP.

A case--control study from Taipei, Taiwan, on the effects of phthalate exposure and filaggrin gene variants on atopic dermatitis showed that children with specific filaggrin genotypes had higher urinary concentrations of phthalates, suggesting that such genotypes may increase skin permeability and so may lead to the higher absorption of phthalates and result in increased susceptibility to atopic dermatitis in such children ([@c58]). In terms of mechanisms, phthalates might impair the epidermal barrier development processes. In addition, skin barrier defects caused by filaggrin gene mutations may allow allergens or irritants to penetrate the epidermis and to interact with antigen-presenting cells, phenomena which lead to the development of atopic dermatitis ([@c45]; [@c57]). A Danish study in children between 3 and 5 y of age found a relationship between atopic dermatitis and MEP in urine, but only in the fourth quartile, and no association with MiBP, a DiBP metabolite, while other metabolites of DiNP were not investigated ([@c16]). Our study shows associations between prenatal phthalate exposure and atopy as assessed by total IgE at 5 y of age based on total IgE levels; however, findings in a study of another birth cohort did not observe an association based on specific IgE levels ([@c22]). In our study, the information on atopy was available for only 48.5% of the study population; hence the results should be interpreted with caution. Studies have suggested that two-thirds of the cases with eczema do not have measurable levels of circulating IgE antibodies ([@c21]). In our study, about one-third (32%) of the boys had allergic eczema and two-thirds (68%) had nonallergic eczema.

Strengths and Limitations {#s5.3}
-------------------------

Our study has several strengths. The population-based prospective cohort design with nutritional, environmental, biological, and social factors starting during prenatal life is a strength of our study that allowed us to control for potential confounders and to assess exposure before the health outcomes. Furthermore, to reduce subject variability, values of the exposure biomarkers were standardized for urine sampling conditions ([@c41]). However, we were limited to one urine sample per mother during the second trimester of pregnancy; thus we were unable to assess the variability in concentrations of each metabolite across the pregnancy. But it is also not clearly known at what point(s) in gestation the infants are at higher risk of exposure. Other studies have also used second-trimester maternal urinary concentration for biomarkers ([@c61]; [@c22]; [@c9]). Consistency in urinary concentrations during pregnancy has been observed for some environmental exposure biomarkers ([@c42]; [@c39]), and other studies have suggested that phthalate biomarkers are relatively stable for a period of weeks to months ([@c27]; [@c25]; [@c55]). Increasing the number of urine samples collected would have provided a more accurate estimate of the average exposure during the gestation period. We also adjusted for many potential confounders; however, residual confounding (if any) cannot be ruled out.

Regarding exposure assessment, it might be important to explore other techniques for assessment of the exposure, particularly those that may offer a more exhaustive and coordinated picture of the individual environment, for instance, by assessing the use of particular items in conjunction with indoor air levels and additional biomarkers of exposure.

Previous studies have reveal sex/gender-specific relationships between phthalates and health ([@c9]; [@c56]). In our study, we considered only male offspring because the initial purpose was to see the effects of phthalates on malformations of male genitalia ([@c48]). Although considering only males limits the generalization of our results, it is not a source of bias. From a statistical point of view, focusing on one sex is another way to increase the study accuracy when the sample size is limited.

The questionnaire data were self-reported and thus could have been subject to misclassification; in addition, recall bias was a possibility that might in part account for the high prevalence of eczema in our study population. The prevalence of early- and late-onset eczema in the present study was 15.7% and 14.7%, respectively, both of which are higher than that found (12.2%) in a cohort study from Poland in children at 2 y of age ([@c53]). However, a study by Augustin et al. ([@c5]) showed a prevalence of 17.13% and 12.87% in children between 0--2 and 3--6 y of age, respectively.

Creatinine correction is most often used for urinary biomarkers of phthalates, phenols, and pesticides. There are limitations to the usage to creatinine to normalize for urine dilution; different investigators have used specific gravity as an alternative to creatinine to adjust phthalate urinary biomarkers for urine dilution ([@c35]; [@c61]), but we did not have specific gravity measurements. Nevertheless, specific gravity is highly correlated with creatinine ([@c8]) and, consequently, we likely overcorrected for urine dilution.

The exposures we studied are relatively prevalent, and some biomarker urinary concentrations approach those with significant effects in experimental models. In a healthy cohort such as ours, effects of hormonally active environmental exposures on skin may be small, yet a continuous exposure can have adverse health effects.

A further dimension to consider in future research is multiple exposures of hormonally active agents such as these phthalates. In terms of prevention, exposure to these chemicals can be avoided if the product contents are already known or are listed on the product label; unfortunately, they are often not listed on the label because of their identification as inactive ingredients.

Conclusions {#s6}
===========

Our data provide new suggestive evidence that prenatal exposure to certain phthalates, including DiBP and DiNP, may play a role in the development of eczema in early childhood. Future research focusing on larger populations and addressing multiple exposures assessed prenatally and postnatally are required to provide more evidence on possible contributions of emerging pollutants to study the role of phthalates on eczema in children.

Supplemental Material
=====================

###### 

Click here for additional data file.
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